The LOX inhibitors (nonselective nordihydroguaiaretic acid, 5-LOX inhibitor Rev-5901, and the 12-LOX inhibitor baicalein) suppressed proliferation of pancreatic cancer cells and decreased survival of prostate cancer cell line [120]. This evidence concerns the gene ALOX5 and prostate carcinoma.